1. An external-control-type fan coupling device being configured such that an inside of a hermetic housing which is formed of a non-magnetic casing which is supported on a rotary shaft body which mounts a drive disc on a distal end thereof by way of a bearing and a cover which is mounted on the casing is divided into an oil reservoir chamber and a torque transmission chamber which houses the drive disc therein by a partition plate which is mounted on the drive disc, the coupling device includes an oil circulation flow passage which is formed between the torque transmission chamber and the oil reservoir chamber and an oil supply adjustment hole which is formed in the partition plate, the coupling device includes a valve element which opens or closes the oil supply adjustment hole in the oil reservoir chamber, and an openclose control of the oil circulation flow passage is performed by operating the valve element using an actuator, and the rotational torque transmission from a drive side to a driven side is controlled by increasing or decreasing an effective contact area of oil in a torque transmission gap portion defined between the drive side and the driven side, wherein
the coupling device adopts a method in which the actuator is arranged in the inside of the rotary shaft body, a control rod which is operated by the actuator penetrates the inside of the rotary shaft body in the axial direction so as to control the valve element, the coupling device includes a primary coil which is fixed to the outside and a secondary coil which is fixed to the rotary shaft body and faces the primary coil in an opposed manner, and the actuator which is mounted in the rotary shaft body is driven by an electric current induced to the secondary coil.
2. The external-control-type fan coupling device according to claim 1, wherein the coupling device adopts a method which rectifies an AC current induced to the secondary coil into a DC current by a rectifier and the actuator is driven using the DC current.
3. The external-control-type fan coupling device according to claim 2, wherein either one of a rotary-type solenoid type actuator or a linear-type solenoid type actuator is used as the actuator.
4. The external-control-type fan coupling device according to claim 1, wherein either one of a rotary-type solenoid type actuator or a linear-type solenoid type actuator is used as the actuator.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A ready-to-administer parenteral dosage form comprising
a. an aqueous solution comprising
I. therapeutically effective amount of norepinephrine or its pharmaceutically acceptable salt and
II. an antioxidant which is not a sulphite antioxidant
wherein the aqueous solution is stable at room temperature.
2. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein the antioxidant is selected from butylated hydroxyl anisole, ascorbic acid, sodium ascorbate, propyl gallate, vitamin E or alpha-tocopherol.
3. The ready-to-administer parenteral dosage form as claimed in claim 2, wherein the anti-oxidant is butylated hydroxyl anisole.
4. The ready-to-administer parenteral dosage form as claimed in claim 3, wherein butylated hydroxyl anisole is present in the aqueous solution in an amount ranging from about 0.001 mgml to about 0.01 mgml.
5. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein norepinephrine is present in an amount ranging from about 0.001 mgml to about 0.2 mgml.
6. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein norepinephrine or its pharmaceutically acceptable salt is norepinephrine bitartarate.
7. The ready-to-administer parenteral dosage form as claimed in claim 6, wherein norepinephrine bitartarate is present in an amount ranging from about 0.002 mgml to about 0.4 mgml.
8. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein the pH of the aqueous solution is in the range of about 3.0 to about 4.5.
9. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein the aqueous solution is filled in a container, which optionally is further packaged in a secondary packaging, wherein either the container or the secondary packaging is designed to protect the solution from light.
10. The ready-to-administer parenteral dosage form as claimed in claim 9, wherein the container is made up of a material selected from the group comprising polyolefin polymers, polyethylene, polypropylene; cyclo olefin polymers, cyclo olefin copolymers; polypropylene based polyolefin polymers; polycarbonates; modified polyolefin-polyethylene polymers; styrene-polyolefin based polymers and block co-polymers thereof.
11. The ready-to-administer parenteral dosage form as claimed in claim 9, wherein the secondary packaging comprises an aluminium pouch and an oxygen scavenger.
12. The ready-to-administer parenteral dosage form as claimed in claim 9, wherein the container is a pre-filled syringe and wherein norepinephrine is present in the aqueous solution in an amount ranging from about 0.05 mgml to about 0.2 mgml.
13. The ready-to-administer parenteral dosage form as claimed in claim 9, wherein the container is an infusion bag and wherein norepinephrine is present in the aqueous solution in an amount ranging from about 0.004 mgml to about 0.15 mgml.
14. The ready-to-administer parenteral dosage form as claimed in claim 1, wherein the parenteral dosage form is stable at room temperature and wherein the value of total impurities in the aqueous solution is not more than 2.0% by weight upon storage at room temperature or lower for at least 12 months.
15. A ready-to-administer parenteral dosage form comprising an aqueous solution comprising
therapeutically effective amount of norepinephrine or its pharmaceutically acceptable salt an anti-oxidant which is not a sulphite antioxidant
wherein the solution when stored at room temperature for twelve months has less than 4% of S-isomer content.